- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01132664
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
A Phase Ib/II, Open Label, Multi-center Study Evaluating the Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab
This study will assess the safety and efficacy of BKM120 in combination with trastuzumab in patients with relapsing HER2 overexpressing breast cancer who have previously failed trastuzumab.
The study will further assess the safety and preliminary efficacy of BKM120 in combination with trastuzumab and capecitabine in patients with relapsing HER2 overexpressing breast cancer and brain metastases (BM) who have previously failed trastuzumab.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Liege, België, 4000
- Novartis Investigative Site
-
Wilrijk, België, 2610
- Novartis Investigative Site
-
-
-
-
-
Lyon Cedex, Frankrijk, 69373
- Novartis Investigative Site
-
Saint-Herblain Cédex, Frankrijk, 44805
- Novartis Investigative Site
-
-
-
-
CA
-
Cagliari, CA, Italië, 09134
- Novartis Investigative Site
-
-
MC
-
Macerata, MC, Italië, 62100
- Novartis Investigative Site
-
-
MO
-
Modena, MO, Italië, 41100
- Novartis Investigative Site
-
-
TR
-
Terni, TR, Italië, 05100
- Novartis Investigative Site
-
-
-
-
Catalunya
-
Barcelona, Catalunya, Spanje, 08035
- Novartis Investigative Site
-
Hospitalet de LLobregat, Catalunya, Spanje, 08907
- Novartis Investigative Site
-
-
Comunidad Valenciana
-
Valencia, Comunidad Valenciana, Spanje, 46010
- Novartis Investigative Site
-
-
-
-
-
Nottingham, Verenigd Koninkrijk, NG5 1PB
- Novartis Investigative Site
-
Oxford, Verenigd Koninkrijk, OX3 7LJ
- Novartis Investigative Site
-
-
East Sussex
-
Brighton, East Sussex, Verenigd Koninkrijk, BN2 5BE
- Novartis Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35294-0006
- University of Alabama at Birmingham/ Kirklin Clinic Univ AL - PI
-
-
Arkansas
-
Fayetteville, Arkansas, Verenigde Staten, 72703
- Highlands Oncology Group Dept of Highlands Oncology Grp
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48201
- Karmanos Cancer Institute Dept.of KarmanosCancerInst (6)
-
-
Missouri
-
St. Louis, Missouri, Verenigde Staten, 63110
- Washington University School Of Medicine-Siteman Cancer Ctr WA Siteman
-
-
New York
-
New York, New York, Verenigde Staten, 10003
- Beth Israel Medical Center BIMC
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Sarah Cannon Research Institute Sarah Cannon Cancer Center SC
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- World Health Organization (WHO) Performance Status of ≤ 2
- Patients with HER2+ breast cancer by local laboratory testing (immunohistochemistry [IHC] 3+ staining or fluorescence in situ hybridization [FISH] confirmation for IHC 2+ and 1+)
Documented tumor resistance to trastuzumab:
- Recurrence while on trastuzumab or within 12 months since the last infusion for patients who received trastuzumab as adjuvant treatment
- Progression while on or within 4 weeks since the last infusion of trastuzumab for patients who received trastuzumab for metastatic disease.
Documented evidence of progressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) on trastuzumab-based therapy defined as:
- Phase Ib: at any time before study entry
- Phase II: within 16 weeks before date of first dosing
Received at least 1 but no more than 4 prior anit-HER2 based regimens including at least 1 regimen containing trastuzumab (adjuvant or neo-adjuvant trastuzumab will be considered as one prior regimen). HER2 directed therapies are defined as comprising trastuzumab, lapatinib, and trastuzumab-DM1 (T-DM1) only.
• Phase II only: trastuzumab, T-DM1 or lapatinib must be part of the most recent line of therapy
Previous lines of cytotoxic chemotherapy:
- Phase Ib: no more than 4 lines of cytotoxic chemotherapy
- Phase II: no more than 3 lines of cytotoxic chemotherapy
Measurable disease:
- Phase Ib: patient has at least one measurable lesion or non-measurable disease as defined per RECIST
- Phase II: patient has at least one measureable lesion as defined per RECIST
|| Specific Inclusion Criteria for patients in BM cohorts:
- Patient has evidence of progressing brain metastases and/or new metastatic brain lesion(s) without leptomeningeal disease.
- Patient has received prior WBRT and/or SRS at at >28 and >/= 14 days, respectively, prior to starting study drug and the patient must have recovered from the side effects of the therapy
- WHO performance status of </=1
- PT INR </= 1.5
- Any number of prior HER2-directed and cytotoxic regimens, and the most recent line may be any type of anti-neoplastic therapy
|| Exclusion Criteria:
- Patients with untreated brain metastases
- Patients with acute or chronic liver, renal disease or pancreatitis
- Patients with any peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events (CTCAE) grade 2
- Patients with a history of mood disorders or ≥ CTCAE grade 3 anxiety
- Patient with clinical manifest diabetes mellitus or steroid-induced diabetes mellitus
|| Specific Exclusion Criteria for patients in BM cohorts
- Prior treatment with capecitabine
- Patient has known dihydropyrimidine dehydrogenase (DPD) deficiency
- Patient is currently receiving treatment with EIAED
- Other protocol-defined inclusion/exclusion criteria may apply
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: HER2+ metastatic breast cancer
Patients with HER2-overexpressing metastatic breast cancer, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
|
Buparlisib (BKM120) is the investigational drug.
Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules.
Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
Trastuzumab was used in this study according to the local regulations in each participating country.
A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
|
Experimenteel: HER2+ metastatic breast cancer with BM
Patients with HER2-overexpressing metastatic breast cancer and brain metastases, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
|
Buparlisib (BKM120) is the investigational drug.
Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules.
Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
Trastuzumab was used in this study according to the local regulations in each participating country.
A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Dose Limiting Toxicity (DLT) - Phase l Only
Tijdsspanne: cycle 1 - 28 days
|
Determination of the maximum tolerated dose (MTD) in the dose escalation part of the study was based upon the estimation of the probability of DLT in Cycle 1 in patients of the dose-determining set.
|
cycle 1 - 28 days
|
Overall Response Rate (ORR) - Phase ll
Tijdsspanne: 18 months
|
Objective response rate (ORR) was defined as the rate of patients with best overall response (BOR) equal to complete response (CR) or partial response (PR) according to RECIST 1.0 from the Investigators review. Per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0 assessed of the disease status by imaging (i.e. CT/MRI): Complete Response (CR) = Disappearance of all tumor lesions; Partial Response (PR)= >=30% shrinkage of lesions; Overall Response (OR) = patients with CR and PR. |
18 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Disease Control Rate (DCR) Based on Investigator Assessment- Phase l & ll
Tijdsspanne: 18 months
|
Disease control rate (DCR) = patients with complete response (CR), partial response (PR) or stable disease (SD) as per RECIST criteria. Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0 assessed the disease status by imaging (i.e. CT/MRI): CR = disappearance of all tumor lesions; PR = >=30% shrinkage of lesions; SD = Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease (PD); PD = At least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline. |
18 months
|
Clinical Benefit Rate (CBR) - Phase l & ll
Tijdsspanne: 18 months
|
CBR = patients with CR, PR or SD ≥ 24 weeks according to RECIST by the investigator. Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0 assessed the disease status by imaging (i.e. CT/MRI): CR = Disappearance of all tumor lesions; PR= >=30% shrinkage of lesions; SD = Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD; PD = At least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline. |
18 months
|
Progression Free Survival (PFS) - Based on Investigator Review Using Kaplan Meier - Phase l & ll
Tijdsspanne: 18 months
|
18 months
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CBKM120X2107
- 2009-015417-46 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Uitgezaaide borstkanker
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University en andere medewerkersVoltooidDe klinische toepassingsgids van Conebeam Breast CTChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op BKM120
-
ARCAGY/ GINECO GROUPVoltooid
-
Novartis PharmaceuticalsVoltooidPI3K Pathway-geactiveerde tumorenVerenigde Staten
-
Novartis PharmaceuticalsNovartisIngetrokkenBehandeling voor gemetastaseerde of lokaal gevorderde baarmoederhalskankerBrazilië
-
Prince of Songkla UniversityBeëindigdSlokdarmkankerThailand
-
Novartis PharmaceuticalsVoltooidGeavanceerde vaste tumorJapan
-
M.D. Anderson Cancer CenterNovartisVoltooid
-
Hospices Civils de LyonOnbekend
-
Sofia Perea, Director Clinical Trials Unit.NovartisVoltooid
-
Won KimNovartisBeëindigdProstaatkanker met een hoog risicoVerenigde Staten
-
Novartis PharmaceuticalsVoltooidGeavanceerde endometriumkankerBelgië, Frankrijk, Italië, Canada, Spanje, Australië, Duitsland, Verenigde Staten, Japan, Brazilië, Singapore, Russische Federatie, Polen